Muscular Dystrophy Association
3300 E. Sunrise Drive
79 articles with Muscular Dystrophy Association
33 Organizations Representing Millions of Patients Urge Policymakers to Adopt "Patient-First" Policy Agenda
A coalition of 33 organizations representing millions of people with pre-existing conditions launched an unprecedented effort by releasing their top priorities for the next Administration.
Muscular Dystrophy Association Awards Five Grants Totaling Over $1.6 Million for Amyotrophic Lateral Sclerosis (ALS) Research
MDA continues to step up fight against ALS during this challenging time, building on its $168 million research commitment
Muscular Dystrophy Association Announces Relaunch of Iconic Telethon Hosted by Actor & Comedian Kevin Hart
The Muscular Dystrophy Association announced the relaunch of their legendary Jerry Lewis MDA Telethon with Kevin Hart joining as host.
MDA Advocacy Institute - Facebook Live - Q&A: Accessible Voting in the 2020 Election for People with Disabilities -- Featuring U.S. Senator Bob Casey, Hosted by MDA's Kristin Stephenson, Friday, September 11 at 2:30pm ET
What: The Muscular Dystrophy Association's Advocacy Institute invites you to join a special virtual conversation on Facebook Live featuring U.S.
Jiffy Lube® Teams Up with Muscular Dystrophy Association for 9th Annual MUSCLE UP! Campaign to Fund Research and Care for Neuromuscular Community
Jiffy Lube and the Muscular Dystrophy Association are teaming up for the ninth annual MUSCLE UP!℠ campaign.
After almost 15 years since the first gene therapy trial for Duchenne muscular dystrophy (DMD) began, the dream of a DMD gene therapy drug is getting closer to a reality.
MDA's Annual Summer Camp for Children with Neuromuscular Diseases Launches Virtually for 65th Session
The Muscular Dystrophy Association announced its annual summer camp, which services more 3,000 children ages 8 to 17 living with neuromuscular diseases, will be held virtually in response to the COVID-19 pandemic.
MDA Frontline COVID-19 Response: Facebook Live Q&A to Protect the Neuromuscular Disease Community in Reopening with Dr. John W. Day on Monday, June 15 at 3pm
The Muscular Dystrophy Association invites you to join a special virtual conversation on Facebook Live featuring MDA Medical Consultant Dr. John W. Day and MDA Director of Care Center Programs, Marydeth Guerin
Drink One for Dane: Customers help Dutch Bros Coffee raise $1.39 million to support Muscular Dystrophy Association's fight to end ALS
Dutch Bros Coffee and its customers joined together to raise $1.39 million for the Muscular Dystrophy Association on the company's 14th annual Drink One For Dane day held on May 8. More than 390 shops in seven states joined together with customers to support ALS research, patient care and advocacy.
Muscular Dystrophy Association's COVID-19 Emergency Fund Launches Extensive Campaign in ALS Awareness Month to Raise Funds for the Most Vulnerable During the Pandemic
Now available - On-demand webinar for ALS families on how to manage stress during COVID-19 pandemic May 1 , 3 p.m. ET - Facebook Live @MDAorg with leading ALS expert Dr. Matthew Harms May 1
MDA Frontline COVID-19 Response: Facebook Live Q&A to Protect the ALS Community with Dr. Matthew B. Harms
The Muscular Dystrophy Association invites you to join a special virtual conversation on Facebook Live featuring Dr. Matthew B. Harms and Kristin Stephenson, about the precautions and best practices needed to protect the ALS community in the midst of the COVID-19 pandemic.
Muscular Dystrophy Association Announces Formation of Strategic Medical Advisory Team of Experts in Neuromuscular Care and Research
Barry Byrne, MD, PhD, will serve as Chief Medical Advisor; John W. Day, MD, PhD and Matthew B. Harms, MD, to serve as Medical Consultants Dr. Byrne to lead a Facebook Live Conversation on Thursday, April 2 about how people living with muscular dystrophy, ALS and related neuromuscular diseases can navigate the world during the COVID-19 crisis
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich's Ataxia
The Muscular Dystrophy Association and AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich's ataxia, announced the award of MDA Venture Philanthropy funding totaling $1,076,232 to advance AavantiBio's phase 2 clinical trial of a gene-replacement therapy for the disease.
12/20/2019Pharma, biotech and life sciences organizations strengthen their leadership teams and boards.
The Muscular Dystrophy Association Names Steven J. Farella as Chairman and Dr. Donald S. Wood as Vice Chairman of the Board
MDA is focused on driving innovations in research and care for people living with neuromuscular diseases.
Muscular Dystrophy Association Names Sharon Hesterlee, Ph.D., Executive Vice President, Chief Research Officer
An experienced drug development executive focused on neuromuscular disease, neuroscientist Dr. Hesterlee brings a unique background in the pharma, biotech and nonprofit sectors
Casey's General Stores Team Up with MDA in 16 States Across the U.S. to Raise Funds for People Living with Neuromuscular Diseases for the Live Unlimited Campaign
For more than 10 years, Casey's team members and guests have devoted time to raise vital funds for individuals living with neuromuscular diseases in their communities
Bennett Foundation donates $500,000 to Muscular Dystrophy Association in honor of the late TV Pioneer Bob Bennett
The Muscular Dystrophy Association announced that the Bennett Foundation is graciously donating $500,000 for the Los Angeles area MDA Summer Camp in Orange, California, which will be named the MDA Robert & Marjie Bennett Foundation Summer Camp.
The Muscular Dystrophy Association and Locana, a leading RNA-targeting gene therapy company, announced the award of an MDA Venture Philanthropy grant totaling $550,000 to advance Locana's development program for myotonic dystrophy.
MDA Celebrates FDA Approval of Zolgensma for Treatment of Spinal Muscular Atrophy in Pediatric Patients
The Muscular Dystrophy Association celebrated the decision by the U.S. Food and Drug Administration to grant approval of Zolgensma, the first gene therapy for a neuromuscular disease.